Introductory lecture and student registration

Aims and Scope

To understand the basic functioning of glutamatergic synapses in the brain, with a special emphasis on the properties of glutamate receptors

To understand the primary mechanisms of synaptic plasticity, especially long-term potentiation (LTP) and long-term depression (LTD)

The main goal of this course is to provide more specialised background information that is necessary for graduate students to pursue various cellular and molecular neuroscience projects in the Department of Brain and Cognitive Sciences (BCS). This course will run in parallel with, but will build upon, the core course that will introduce the fundamental principles of the nervous system.

The course will start with a description of the glutamate receptor subtypes and how glutamate synapses operate in the brain. This will pave the way for a detailed discussion of the mechanisms of synaptic plasticity, in particular longterm potentiation (LTP) and long-term depression (LTD) in various brain regions. The relevance of synaptic plasticity for learning & memory will be described. In addition, how synaptic plasticity is being studied in the context of experimental models of neurological and psychiatric disorders will also be discussed.

Most seminars will last 2-3 hours and will typically be divided into two blocks of teaching of approximately 1 hour each, with a coffee break in between. There will be two types of "seminars". Each topic will start with didactic teaching to introduce the subject. Students will then have time to prepare for their presentations. Student presentations will involve presenting a recent research publication (journal club style). Towards the end of the course students will be divided into teams to write a grant application.

This course will enable the students to engage in self-directed learning. It will involve research, team work and verbal presentations.

Reading materials:

General reading: Neuroscience: Exploring the Brain (3rd Edition, by Mark Bear, Barry Connors, and Michael Paradiso) (Each seminar will have specific additional reading material)

Grading criteria:

Attendance (10%) In-class attitude & class participation (15%) Journal club presentations (25%) Project (50%) total (100%)

Week 1 (Sep 7): Lecture 1: Lecture 2:	Introduction to the Course History of iGluRs.	Graham Collingridge Graham Collingridge
Week 2 (Sep 14): Lecture 3 Lecture 4	AMPA & NMDA receptors. Kainate receptors	Graham Collingridge
Week 3 (Sep 21): No Class	Thanksgiving	
Week 4 (Sep 28):	Preparation time:	

Week 5 (Oct 5): Journal Club on iGluRs.

Week 6 (Oct 8): Journal Club on iGluRs

Week 7 (Oct 19): Lecture 5: Lecture 6;	LTP in the hippocampus 1 LTP in the hippocampus 11	Tim Bliss Graham Collingridge
Week 8 (Oct 26):	The LTP debate	
Week 9 (Nov 2): Lecture 7: Lecture 8:	LTD in the hippocampus 1 LTD in the hippocampus 2	Graham Collingridge Graham Collingridge
Week 10 (Nov 9):	Journal Club on LTD	


Week 11 (Nov 16)

Journal Club on LTD

Week 12 (Nov 23)

Select and discuss research proposal

Week 13 (Nov 30) Project Prepare research proposal




Week 14 (Dec 7) Project presentations




Week 15 (Dec 14) Feedback on research presentations, course marks and feedback. L-GLUTAMATE: THE MAJOR EXCITATORY NEUROTRANSMITTER IN THE CNS

Glutamate excites central neurons



Jeff Watkins



IONOTROPIC GLUTAMATE RECEPTORS

Early studies identified two classes of glutamate receptor termed glutamate preferring and aspartate preferring

1962 - NMDA (N-methyl-D-aspartate) synthesised by Jeff Watkins

Discovery of quisqualate (a natural product) was followed by the naming of the two receptors: NMDA and quisqualate (or non-NMDA) receptors

Discovery of selective NMDA receptor antagonists soon followed:

D- α -aminoadipate (D α AA)

Mg²⁺ ions


2-amino-5-phosphonovalerate / D-2-amino-5-phosphonopentanoate (2APV or D-AP5) (Davies et al, 1981 *Neurosci Lett*, 21, 77-81)

Ketamine & phencyclidine (PCP)

glycine-site antagonists


NMDARs mediate synaptic transmission

(first direct evidence that L-glutamate is an excitatory neurotransmitter)




Davies & Watkins, (1979) J. Physiol. 297, 621-636


Mg²⁺ is a potent, selective NMDA antagonist




Dissociative anaesthetics (ketamine, phencyclidine etc) are selective NMDAR antagonists



Discovery of the glycine co-agonist site and glycine site antagonists





Johnson & Ascher, (1987) Nature. 325, 529-531

Fletcher & Lodge (1988) Eur J Pharmacol 151, 161-162


AMPA RECEPTORS

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) was synthesised.

Quisqualate receptor renamed the AMPA receptor

AMPA RECEPTORS


AMPA excites central neurons



Krogsgaard-Larsen et al, (1980) Nature. 284, 64-66

KA RECEPTORS

Direct evidence for kainate receptors: KA specifically depolarises dorsal routes.



Agrawal & Evans, (1986) Br J Pharmacol. 87, 345-355

AMPA RECEPTORS

First AMPAR antagonists developed


(e.g., GDEE, glutamate diethyl ester; DGG; γ-D-glutamylglycine) Evidence that AMPARs mediate synaptic transmission

Discovery of quinoxalinediones (DNQX, CNQX, NBQX) Ability to completely block AMPAR transmission but spare NMDAR transmission

Discovery of GYKI compounds (GYKI52466, GYKI53655) Able to block AMPAR but spare kainate receptor transmission

AMPA RECEPTORS

Quinoxalinediones selectively antagonise AMPARs and KARs



IONOTROPIC GLUTAMATE RECEPTORS

Receptors of major neurotransmitter in brain

Three main classes - AMPA, NMDA, kainate (KA)

Composed of four subunits

Subunit composition affects properties

METABOTROPIC GLUTAMATE RECEPTORS

Receptors of major neurotransmitter in brain

Eight subtypes, divided into three groups - I, II and III


G-protein coupled receptors

Can be inhibitory as well as excitatory

IONOTROPIC GLUTAMATE RECEPTORS

Subunits share sequence homology - IUPHAR nomenclature

http://www.iuphar-db.org/nomenclature.html




IUPHAR nomenclature and previous nomenclature

http://www.genenames.org/

<u>Subunit</u>	Gene	Old subunit names
GluA1	GRIA1	GLU _{A1} , GluR1, GluRA, GluR-A, GluR-K1, HBGR1
GluA2	GRIA2	GLU _{A2} , GluR2, GluRB, GluR-B, GluR-K2, HBGR2
GluA3	GRIA3	GLU _{A3} , GluR3, GluRC, GluR-C, GluR-K3
GluA4	GRIA4	GLU _{A4} , GluR4, GluRD, GluR-D
GluK1	GRIK1	GLU _{K5} , GluR5, GluR-5, EAA3
GluK2	GRIK2	GLU _{K6} , GluR6, GluR-6, EAA4
GluK3	GRIK3	GLU _{K7} , GluR7, GluR-7, EAA5
GluK4	GRIK4	GLU _{K1} , KA1, KA-1, EAA1
GluK5	GRIK5	GLU _{K2} , KA2, KA-2, EAA2
GluN1	GRIN1	GLU _{N1} , NMDA-R1, NR1, GluRξ1
GluN2A	GRIN2A	GLU _{N2A} , NMDA-R2A, NR2A, GluR1
GluN2B	GRIN2B	GLU _{N2B} , NMDA-R2B, NR2B, hNR3, GluR2
GluN2C	GRIN2C	GLU _{N2C} , NMDA-R2C, NR2C, GluR3
GluN2D	GRIN2D	GLU _{N2D} , NMDA-R2D, NR2D, GluR4
GluN3A	GRIN3A	GLU _{N3A} , NMDA-R3A, NMDAR-L, chi-1
GluN3B	GRIN2B	GLU _{N3B} , NMDA-R3B
GluD1	GRID1	GluRδ1
GluD2	GRID2	GluRδ2
lu =	= RI	

Collingridge et al, (2009) Neuropharmacology, 56, 2-5.

Schematic of the three structural categories of ligand-gated ion channel subunit.



All glutamate receptor subunits have the membrane topology of an extracellular N-terminus, three transmembrane domains (formed by M1, M3 and M4), a channel lining re-entrant 'p-loop' (M2) located between M1 and M3 that enters and exits the membrane at its cytoplasmic surface, and an intracellular C-terminus

Collingridge et al, (2009) Neuropharmacology, 56, 2-5.

Long term potentiation: the synaptic basis of memory

J. Physiol. (1973), 232, pp. 331–356 With 12 text-figures Printed in Great Britain




LONG-LASTING POTENTIATION OF SYNAPTIC TRANSMISSION IN THE DENTATE AREA OF THE ANAESTHETIZED RABBIT FOLLOWING STIMULATION OF THE PERFORANT PATH

BY T. V. P. BLISS AND T. LØMO


From the National Institute for Medical Research, Mill Hill, London NW7 1AA and the Institute of Neurophysiology, University of Oslo, Norway

(Received 12 February 1973)



331

Bi-directional synaptic plasticity: LTP and LTD



Tuesday, 7 September 2010

READING

Collingridge et al, (2009) Neuropharmacology, 56, 2-5.

Lodge (2009) Neuropharmacology, 56, 6-21.